Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)

Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)

Abstract Background PEGylated nanoparticles (PEG-NPs) are not effective for hematologic malignancies as they lack the enhanced permeability and retention effect (EPR effect). Tumor-targeted PEG-NPs can systemically track lymphoma and actively internalize into cancer cells to enhance therapeutic effi...

Full description

Bibliographic Details
Main Authors: Huei-Jen Chen, Yi-An Cheng, Yu-Tung Chen, Chia-Ching Li, Bo-Cheng Huang, Shih-Ting Hong, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Fang-Ming Chen, Jaw-Yuan Wang, Steve R. Roffler, Tian-Lu Cheng, Dung-Ho Wu
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Cancer Nanotechnology
Subjects:
PEGylated nanoparticles (PEG-NPs)
Enhanced permeability and retention effect (EPR effect)
Anti-PEG bispecific antibody (BsAb; mPEG × CD20)
CD20-armed liposomes
αCD20/PLD
Hematologic malignancies
Online Access:https://doi.org/10.1186/s12645-023-00230-6

Internet

https://doi.org/10.1186/s12645-023-00230-6

Similar Items